Bahrain NHRA Pharmaceutical Import: A 2026 Guide for UK Exporters

Bahrain is a compact but strategically important pharmaceutical market within the Gulf. A high standard of tertiary care, a centralised public health system led by the Ministry of Health, and a regulatory framework that aligns closely with international norms make the Kingdom a market where UK-licensed, MHRA-authorised medicines are well understood and well regarded. For hospitals, the Ministry of Health, and licensed distributors sourcing UK-licensed finished medicines, the gateway to compliant supply is a single body: the National Health Regulatory Authority, the NHRA.

This guide is written for hospital procurement teams, Ministry of Health buyers, and NHRA-registered importers and distributors in Bahrain who want a clear, practical view of how to import and register UK-licensed medicines in 2026. It is also written for UK manufacturers and licensed wholesale exporters who supply into the Bahraini market and need to understand what their Bahraini buyer requires from them. It covers the regulator's role, the general registration and import-permit pathway, the documentation typically required, the named patient import route, serialisation and labelling rules, cold chain expectations, and the most common pitfalls, then explains how Euro Biom supports the UK supply leg.

The NHRA: Bahrain's Medicines Regulator

The National Health Regulatory Authority is the independent government body responsible for regulating health services and products in the Kingdom of Bahrain. Within the NHRA, the section that matters most to anyone importing medicines is the Pharmacy and Pharmaceutical Product Regulation section, usually referred to as the PPR.

The PPR is responsible for licensing medicines for sale in Bahrain, approving and licensing the pharmaceutical companies and importers that handle them, issuing the permissions that allow a consignment to enter the country, and operating the national track and trace system that follows a medicine from the manufacturing site through to the patient. In practice, three principles flow from the NHRA framework and shape everything a UK exporter and a Bahraini buyer do together:

• Every medicine must be licensed. A pharmaceutical product can only be marketed and dispensed in Bahrain once it holds an NHRA medicine licence, unless it is being supplied under a specific exception such as the named patient route.
• Import is only through an authorised entity. Bahrain's pharmacy law requires that the importation of a pharmaceutical product is carried out through an authorised legal entity. A UK exporter does not import directly; the NHRA-registered Bahraini importer or local agent holds the import permission and is the consignee of record.
• Quality and traceability are enforced end to end. Good Manufacturing Practice, country-of-origin certification, bilingual labelling, and serialised track and trace are not optional extras. They are checked at registration and at import.

For UK suppliers, the helpful reality is that the documentation a Bahraini buyer needs maps cleanly onto what the MHRA already issues for a UK-licensed product. The work is in assembling it correctly and getting the sequencing right, not in creating anything that does not already exist.

The General Registration and Import Pathway

There are two broad ways a UK-licensed medicine reaches a Bahraini hospital or pharmacy: full NHRA medicine registration for routine, repeat supply, and the named patient route for a one-off, patient-specific need. Most ongoing commercial supply runs through registration; urgent or rare clinical needs run through the named patient route. Both are covered below.

Step 1: Establish the authorised importer

Before any product moves, there must be an NHRA-registered importing entity in Bahrain. A pharmaceutical company or importer is established through commercial registration on the Sijilat portal, NHRA approval of the establishment, the appointment of a licensed pharmacist, and compliance with storage and premises requirements. This establishment registration is commonly completed within several weeks, subject to inspection and document review. UK exporters supply through this entity; they do not need to establish their own presence in Bahrain.

Step 2: Submit the medicine registration dossier

To license a medicine, an application is made to the NHRA containing the data that supports the product's quality, safety and efficacy. The dossier is structured in the Gulf Health Council and ICH Common Technical Document format and submitted electronically. The reviewer assesses the quality module, the product information, the manufacturing and certification evidence, and the labelling. A granted NHRA medicine licence is valid for five years and is renewable.

Step 3: Obtain import permission for the consignment

Once a product is registered, individual shipments still require import permission handled by the NHRA-registered importer. This is where the country-of-origin documentation, batch release, and Certificate of Analysis travel with the consignment so that the importer can clear the goods and the NHRA can verify them.

Step 4: The named patient route, where registration does not apply

Where a specific patient needs a medicine that is not registered or not stocked in Bahrain, the NHRA operates a named patient import route. A treating physician at a registered healthcare facility applies to import a specific medicine for that named patient, on the basis that the medicine is approved by a recognised reference authority such as the MHRA, EMA, US FDA, Health Canada or PMDA Japan. This is described in detail in its own section below.

Documentation the NHRA Typically Requires

For a full medicine registration of a UK-manufactured, UK-licensed product, the core documentation package generally includes the elements below. Exact requirements are set by current NHRA guidance and should always be confirmed with the Bahraini importer or local agent for the specific product class, but in general terms this is the package a UK supplier should expect to provide or coordinate.

The CPP is the document UK exporters most often underestimate. The NHRA requires a current CPP in WHO format, legalised, and issued in the country of origin. UK manufacturers obtain the CPP from the MHRA Export Certificate service, and the legalisation step, which usually involves the Foreign, Commonwealth and Development Office and the relevant consular process, takes additional time on top of the MHRA turnaround. Building the CPP and its legalisation into the project plan early is essential, particularly where a registration or tender deadline is fixed. For a fuller treatment of the export documentation set, see our UK pharmaceutical import documentation guide.

Batch release is the second area that needs coordination. Each batch shipped to Bahrain should be accompanied by a Qualified Person batch release certificate issued by the manufacturer or a UK-licensed contract release site. Where the UK exporter is not the manufacturer, the wholesale exporter coordinates with the manufacturer's Qualified Person to secure the release documentation ahead of despatch, so it travels with the goods rather than being chased after the fact.

How UK-Licensed Supply Fits the NHRA Framework

Bahrain's regulatory framework gives a clear advantage to products that already hold a marketing authorisation from a stringent regulator. A UK-licensed, MHRA-authorised finished medicine arrives with exactly the documentary trail the NHRA expects: a recognised marketing authorisation, a CPP confirming the licence and the GMP status of the site, batch release by a Qualified Person, and a Certificate of Analysis against an approved specification.

This matters in two ways. For full registration, the MHRA documentation forms the backbone of the quality and certification modules of the dossier. For the named patient route, the fact that the product is approved by the MHRA, a recognised reference authority, is precisely the condition that allows a Bahraini physician to apply to import it for a specific patient. In both cases the UK-licensed status of the product is the asset.

It is worth being precise about scope. Euro Biom supplies UK-licensed, MHRA-authorised finished medicines. The named patient route is the buyer's in-country regulatory mechanism to import a product that is licensed in the UK but not yet registered in Bahrain. It is not a route for supplying an unlicensed product; the medicine is licensed in the UK, and the named patient application is simply how the Bahraini buyer lawfully imports that UK-licensed product for an individual patient.

The Named Patient Import Route

Even in a well-supplied market, hospitals encounter patients who need a medicine that is not registered locally, or that is registered but temporarily unavailable. The NHRA named patient import route exists for exactly this situation, and it is one of the most relevant pathways for UK-licensed specialty supply into Bahrain.

The mechanics are buyer-led. The application is made by the treating physician at a registered healthcare facility, not by the UK supplier. The physician identifies the specific patient and the specific medicine, and applies to the NHRA to import it on the basis that it is approved by a recognised reference authority. UK-licensed products satisfy this condition because the MHRA is a recognised reference authority. The NHRA authorises a patient-specific consignment rather than granting a marketing licence, which is why this route is far quicker than full registration.

The UK supplier's job is to make the physician's application easy to support. That means having the country-of-origin certification, the Certificate of Analysis, and the batch documentation ready so the importer and the facility can attach them to the application. Where Euro Biom supplies under this route, we assemble that pack on the UK side so that the Bahraini buyer's named patient application is supported by clean, consistent documentation. Our named patient supply service describes the UK side of this in more detail.

When the named patient route is the right one

• Specialty medicines with no registered Bahraini equivalent
• A registered product that is in temporary shortage and where a UK-licensed equivalent can bridge supply
• Individual clinical needs where the volume does not justify full registration
• New therapies recently licensed by the MHRA but not yet registered in Bahrain

Serialisation, Labelling and Track and Trace

Bahrain has invested heavily in supply-chain integrity, and serialisation is a genuine, enforced requirement rather than a future ambition. Under Legislative Decree No. 41 of 2017 the NHRA operates a national track and trace system covering the medicine supply chain from manufacturing site to patient.

The practical requirements UK exporters and Bahraini importers should plan around are:

• GS1 Data Matrix on every pack. Packs must carry a two-dimensional Data Matrix barcode encoding the GTIN, expiry date, batch or lot number, and a unique serial number.
• Traceability hub registration. Marketing authorisation holders, manufacturers, importers and distributors are expected to register with the NHRA traceability hub and submit serialisation and aggregation data.
• Global Location Number. Importing agents typically need a GS1 Global Location Number to transact within the national systems and to exchange the electronic events that the track and trace framework relies on.
• Bilingual labelling. The NHRA requires clear English and Arabic labelling across the carton, label and leaflet, alongside the alcohol and pork-derived content declarations.

For a UK exporter the key action is to confirm the serialisation status of each pack with the manufacturer before despatch, and to align early with the Bahraini importer on traceability hub registration, so that consignments are not held while serialisation data is reconciled after arrival.

Cold Chain and GDP Expectations

A meaningful share of UK pharmaceutical supply into Bahrain involves temperature-sensitive product, and Good Distribution Practice is expected throughout the chain. The summer ambient temperatures in the Gulf make cold chain discipline non-negotiable for products that must be held within a defined range.

The core expectations are familiar to any GDP-compliant UK exporter: validated temperature-controlled storage at the UK end, qualified shipping containers specified for the route and the destination ambient profile, a calibrated temperature data logger accompanying the consignment for the entire journey, and stability data supporting the actual transit conditions. The Heathrow to Bahrain routing is short by Gulf standards, with direct flights and a flight time of around six and a half to seven hours, which makes tightly controlled cold chain transit and rapid despatch achievable for both routine and urgent consignments. For the mechanics, see our UK cold chain pharmaceutical supply page.

Common Pitfalls and How to Avoid Them

The same handful of issues account for most of the delay and cost in supplying into Bahrain. Each is avoidable with the right preparation.

1. Underestimating CPP legalisation time

The CPP itself takes weeks to obtain from the MHRA, and legalisation adds more. Treating the CPP as a quick administrative item rather than a multi-week workstream is the most frequent scheduling error. Start it early.

2. Importing without the authorised entity in place

Because import must run through an NHRA-registered entity, attempting to move product before the importer is confirmed and licensed simply stalls. Settle the importer relationship first.

3. Labelling and content declaration gaps

Missing or inconsistent Arabic labelling, or absent alcohol and pork-derived content declarations, are common reasons for hold-ups. Review the labelling pack with the importer before submission and again before each despatch.

4. Serialisation mismatches

Consignments can be delayed where the serialisation data and the physical packs do not reconcile in the national system. Confirm serialisation status and traceability hub alignment with both the manufacturer and the importer before goods move.

5. Batch documentation chased after despatch

Batch release certificates and Certificates of Analysis should travel with the goods. Building them into the export pack template, rather than requesting them once a shipment is already moving, avoids last-minute clearance problems.

6. Treating the named patient route as informal

The named patient route is a defined regulatory mechanism with its own documentation expectations. Aligning the UK supplier pack to what the physician's application needs, from the first request, turns each subsequent case from a scramble into a routine.

How Euro Biom Supports Supply into Bahrain

Euro Biom is a UK MHRA-licensed pharmaceutical wholesale exporter, holding Wholesale Dealer Authorisation WDA(H) 59239. We are not a manufacturer and we are not a regulatory consultancy. We supply UK-licensed, MHRA-authorised finished medicines and operate the UK supply leg of a compliant export, working alongside the Bahraini importer or local agent who holds the NHRA import permissions.

Across the Bahraini pathway, our role typically covers:

• UK-side documentation. Coordinating the MHRA Certificate of Pharmaceutical Product and GMP evidence with the manufacturer or marketing authorisation holder, and assembling the GDP-compliant export pack including the Certificate of Analysis, batch release, packing list, and chamber-attested commercial invoice.
• Named patient support. Providing the country-of-origin certification and batch documentation that a Bahraini physician and importer need to support a named patient import application for a UK-licensed product.
• Cold chain logistics from Heathrow. GDP-validated temperature-controlled storage, qualified shipping containers, calibrated data loggers, and rapid despatch on direct routings to Bahrain.
• Hospital, Ministry and distributor supply. Working with hospital procurement teams, the Ministry of Health, and NHRA-registered distributors to deliver UK-licensed finished medicines reliably and traceably.

For the country overview, see our UK pharmaceutical exporter to Bahrain page. To compare Bahrain's regulator with others across the Gulf, Africa and Asia, use our pharma regulator comparison tool. The full export documentation set is covered in the UK pharmaceutical import documentation guide, the named patient mechanism on the named patient supply page, and our overall capability on the services page. The guide was written by Akhlesh Mathur, Director.